Target family: Neuromedin U receptors (type: gpcr)
Target: NMU2 receptor

Ligand: [125I]neuromedin U-8 (pig) (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.1 pKd
Reference (Journal): Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system.
Published in: J Biol Chem

Ligand: [125I]neuromedin U-25 (human) (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.8 pKd
Reference (Journal): Signaling and ligand binding by recombinant neuromedin U receptors: evidence for dual coupling to Galphaq/11 and Galphai and an irreversible ligand-receptor interaction.
Published in: Mol Pharmacol

Ligand: [125I]neuromedin U-25 (human) (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.8 pKd
Reference (Journal): Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells.
Published in: Pharmacology

Ligand: [125I]neuromedin U-23 (rat) (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.1 pKd
Reference (Journal): Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system.
Published in: J Biol Chem

Ligand: R-PSOP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.04 pKB
Reference (Journal): Discovery and pharmacological characterization of a small-molecule antagonist at neuromedin U receptor NMUR2.
Published in: J Pharmacol Exp Ther

Ligand: PEG40-NMU (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): PEGylation of Neuromedin U yields a promising candidate for the treatment of obesity and diabetes.
Published in: Bioorg Med Chem

Ligand: NY0116 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.770000457763672 pEC50
Reference (Journal): Small-Molecule Neuromedin U Receptor 2 Agonists Suppress Food Intake and Decrease Visceral Fat in Animal Models.
Published in: Pharmacol Res Perspect

Ligand: NM4-C16 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 6.099999904632568 pIC50
Reference (Journal): Small lipidated anti-obesity compounds derived from neuromedin U.
Published in: Eur J Med Chem

Ligand: neuromedin U-8 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system.
Published in: J Biol Chem

Ligand: neuromedin U-8 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.3 pKi
Reference (Journal): Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells.
Published in: Pharmacology

Ligand: neuromedin U-8 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Identification of receptors for neuromedin U and its role in feeding.
Published in: Nature

Ligand: neuromedin U-8 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells.
Published in: Pharmacology

Ligand: neuromedin U-8 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.1 pKi
Reference (Journal): Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells.
Published in: Pharmacology

Ligand: neuromedin U-25 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.9 pKi
Reference (Journal): Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells.
Published in: Pharmacology

Ligand: neuromedin U-25 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Identification of receptors for neuromedin U and its role in feeding.
Published in: Nature

Ligand: neuromedin U-25 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.6 pKi
Reference (Journal): Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells.
Published in: Pharmacology

Ligand: neuromedin U-25 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells.
Published in: Pharmacology

Ligand: neuromedin U-25 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Identification of receptors for neuromedin U and its role in feeding.
Published in: Nature

Ligand: neuromedin U-25 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Signaling and ligand binding by recombinant neuromedin U receptors: evidence for dual coupling to Galphaq/11 and Galphai and an irreversible ligand-receptor interaction.
Published in: Mol Pharmacol

Ligand: neuromedin U-25 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells.
Published in: Pharmacology

Ligand: neuromedin U-25 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system.
Published in: J Biol Chem

Ligand: neuromedin U-25 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system.
Published in: J Biol Chem

Ligand: neuromedin U-23 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system.
Published in: J Biol Chem

Ligand: neuromedin U-23 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells.
Published in: Pharmacology

Ligand: neuromedin U-23 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Identification of receptors for neuromedin U and its role in feeding.
Published in: Nature

Ligand: neuromedin U-23 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.7 pKi
Reference (Journal): Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells.
Published in: Pharmacology

Ligand: neuromedin S-33 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10 pEC50
Reference (Journal): Identification of neuromedin S and its possible role in the mammalian circadian oscillator system.
Published in: EMBO J

Ligand: neuromedin S-33 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.199999809265137 pIC50
Reference (Journal): Identification of neuromedin S and its possible role in the mammalian circadian oscillator system.
Published in: EMBO J

Ligand: HAS-NMU (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide.
Published in: J Pept Sci

Ligand: CPN-219 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.65999984741211 pEC50
Reference (Journal): A chemically stable peptide agonist to neuromedin U receptor type 2.
Published in: Bioorg Med Chem

Ligand: CPN-116 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.1899995803833 pEC50
Reference (Journal): Discovery of selective hexapeptide agonists to human neuromedin u receptors types 1 and 2.
Published in: J Med Chem

Ligand: compound NRA 4 [PMID: 25262941] (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 4.849999904632568 pEC50
Reference (Journal): Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
Published in: Bioorg Med Chem

Ligand: compound 6b [PMID: 24999562] (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Discovery of selective hexapeptide agonists to human neuromedin u receptors types 1 and 2.
Published in: J Med Chem